CA3174361A1 - Tetrahydroisoquinoline compounds as nrf2 activators - Google Patents
Tetrahydroisoquinoline compounds as nrf2 activators Download PDFInfo
- Publication number
- CA3174361A1 CA3174361A1 CA3174361A CA3174361A CA3174361A1 CA 3174361 A1 CA3174361 A1 CA 3174361A1 CA 3174361 A CA3174361 A CA 3174361A CA 3174361 A CA3174361 A CA 3174361A CA 3174361 A1 CA3174361 A1 CA 3174361A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- disease
- fluoro
- mmol
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2005863.2 | 2020-04-22 | ||
| GBGB2005863.2A GB202005863D0 (en) | 2020-04-22 | 2020-04-22 | Therapeutic compounds |
| PCT/GB2021/050973 WO2021214470A1 (en) | 2020-04-22 | 2021-04-22 | Tetrahydroisoquinoline compounds as nrf2 activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3174361A1 true CA3174361A1 (en) | 2021-10-28 |
Family
ID=70860156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3174361A Pending CA3174361A1 (en) | 2020-04-22 | 2021-04-22 | Tetrahydroisoquinoline compounds as nrf2 activators |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230167084A1 (https=) |
| EP (1) | EP4139294B1 (https=) |
| JP (1) | JP7679400B2 (https=) |
| KR (1) | KR20230004720A (https=) |
| CN (1) | CN115667243B (https=) |
| AR (1) | AR121912A1 (https=) |
| AU (1) | AU2021259366A1 (https=) |
| BR (1) | BR112022021244A2 (https=) |
| CA (1) | CA3174361A1 (https=) |
| ES (1) | ES3032247T3 (https=) |
| GB (1) | GB202005863D0 (https=) |
| IL (1) | IL297434A (https=) |
| MX (1) | MX2022013398A (https=) |
| PH (1) | PH12022552775A1 (https=) |
| WO (1) | WO2021214470A1 (https=) |
| ZA (1) | ZA202211465B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021004566A (es) | 2018-10-22 | 2021-06-08 | C4X Discovery Ltd | Compuestos terapeuticos. |
| PE20241779A1 (es) * | 2022-01-07 | 2024-09-03 | Chugai Pharmaceutical Co Ltd | Compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del nrf2 |
| WO2025237912A1 (en) | 2024-05-13 | 2025-11-20 | Astrazeneca Ab | Keap1 inhibitors for use in the treatment of bronchiectasis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003041641A2 (en) * | 2001-11-09 | 2003-05-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| US20140256767A1 (en) * | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| CA2988373A1 (en) * | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| MX2021004566A (es) * | 2018-10-22 | 2021-06-08 | C4X Discovery Ltd | Compuestos terapeuticos. |
-
2020
- 2020-04-22 GB GBGB2005863.2A patent/GB202005863D0/en not_active Ceased
-
2021
- 2021-04-22 US US17/920,226 patent/US20230167084A1/en active Pending
- 2021-04-22 CN CN202180031435.0A patent/CN115667243B/zh active Active
- 2021-04-22 AU AU2021259366A patent/AU2021259366A1/en active Pending
- 2021-04-22 CA CA3174361A patent/CA3174361A1/en active Pending
- 2021-04-22 EP EP21723350.1A patent/EP4139294B1/en active Active
- 2021-04-22 KR KR1020227040550A patent/KR20230004720A/ko active Pending
- 2021-04-22 WO PCT/GB2021/050973 patent/WO2021214470A1/en not_active Ceased
- 2021-04-22 IL IL297434A patent/IL297434A/en unknown
- 2021-04-22 AR ARP210101080A patent/AR121912A1/es unknown
- 2021-04-22 PH PH1/2022/552775A patent/PH12022552775A1/en unknown
- 2021-04-22 BR BR112022021244A patent/BR112022021244A2/pt unknown
- 2021-04-22 MX MX2022013398A patent/MX2022013398A/es unknown
- 2021-04-22 ES ES21723350T patent/ES3032247T3/es active Active
- 2021-04-22 JP JP2022564519A patent/JP7679400B2/ja active Active
-
2022
- 2022-10-19 ZA ZA2022/11465A patent/ZA202211465B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7679400B2 (ja) | 2025-05-19 |
| US20230167084A1 (en) | 2023-06-01 |
| MX2022013398A (es) | 2022-12-13 |
| EP4139294B1 (en) | 2025-04-09 |
| JP2023524206A (ja) | 2023-06-09 |
| BR112022021244A2 (pt) | 2022-12-06 |
| AU2021259366A1 (en) | 2022-11-10 |
| CN115667243B (zh) | 2025-01-07 |
| ZA202211465B (en) | 2025-06-25 |
| WO2021214470A1 (en) | 2021-10-28 |
| IL297434A (en) | 2022-12-01 |
| PH12022552775A1 (en) | 2024-03-25 |
| CN115667243A (zh) | 2023-01-31 |
| GB202005863D0 (en) | 2020-06-03 |
| EP4139294A1 (en) | 2023-03-01 |
| ES3032247T3 (en) | 2025-07-16 |
| AR121912A1 (es) | 2022-07-20 |
| KR20230004720A (ko) | 2023-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4139295B1 (en) | Isoquiniline nrf2 agonists | |
| EP4252755B1 (en) | Therapeutic compounds | |
| EP4139294B1 (en) | Isoquiniline nrf2 agonists | |
| HK40088672B (en) | Isoquiniline nrf2 agonists | |
| HK40088672A (en) | Isoquiniline nrf2 agonists | |
| HK40101413A (en) | Therapeutic compounds | |
| EA049312B1 (ru) | ТЕТРАГИДРОИЗОХИНОЛИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ АКТИВАТОРОВ Nrf2 | |
| HK40088671A (en) | Isoquiniline nrf2 agonists | |
| HK40088671B (en) | Isoquiniline nrf2 agonists | |
| EA047580B1 (ru) | ТЕТРАГИДРОИЗОХИНОЛИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ АКТИВАТОРОВ Nrf2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220930 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240718 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240919 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241001 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250213 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250213 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250410 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250410 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251024 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251028 |